Virtual Symposium – Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
Current and Future Perspectives for Bispecific Antibodies in Multiple Myeloma: Learnings from 2023
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma (MM) is controversial. Between 2008 and 2014…
Health Canada has approved an sNDA for goserelin acetate 10.8 mg every 12 weeks for ER-positive early breast cancer with a high risk of recurrence…
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited development and review.
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a…
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic…
Tip: Hover on a state to see its rate (and 95% C.I.). Click a state to show its counties.
The 2024 SITC Election takes place May 2–16, 2024.
Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.